Background and Objective
Trastuzumab deruxtecan is a novel antibody drug conjugate recently available for both HER2-positive and HER-2 low metastatic breast cancer. Trastuzumab deruxtecan carries a small but significant risk of interstitial lung disease. Published guidelines on monitoring management are available. Real world data of the activity and toxicity of T-DXd is currently limited. The aim of the study is to describe the response of T-DXd and prevalence of toxicity for these patients with metastatic breast cancer.
Sample and setting
Retrospective study with approximately 40 patients treated in SWSLHD from January 2020 to May 2025.
Procedure
A retrospective chart review for breast cancer patients with HER-2 positive and HER2-low metastatic breast cancer, treated with Trastuzumab deruxtecan at SWSLHD within the study period. Treatment response, toxicity, prior lines of treatment and their toxicity, receptor status, metastatic details, BMI and age will be collected. Frequencies and proportions of response (categorised as complete response, partial response, stable or progressive disease), and of toxicity (including pulmonary, cardiac, haematological, renal) will be calculated as well as their confidence intervals.
Result
To be presented at the meeting.
Clinical implications
This retrospective study is assessing the clinical outcomes of treatments in our local institution. This retrospective study will help provide real-world data on the outcome and safety of Trastuzumab deruxtecan in a real-world setting.
It has the benefit of providing a snapshot of treatment efficacy vs toxicity at a local level, as well as provide further information to guide clinical practice and research in this area and perhaps a role in starting early on in the metastatic setting in breast cancer patients.
Results and conclusion will be presented at the meeting.